Standout Papers

Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy 2006 2026 2012 2019 942
  1. Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy (2006)
    Robert L. Avery, Joel Pearlman et al. Ophthalmology
  2. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD (2014)
    Robert L. Avery, Alessandro Castellarin et al. British Journal of Ophthalmology
  3. Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration (2006)
    Robert L. Avery, Dante J. Pieramici et al. Ophthalmology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 74 standout
Sub-graph 1 of 21

Citing Papers

Age-Related Macular Degeneration
2024 Standout
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
5 intermediate papers

Works of Melvin Rabena being referenced

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
2017
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
2006 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Melvin Rabena 2232 1741 66 448 17 2.5k
Ma'an Nasir 2350 1830 56 436 24 2.6k
Alessandro Castellarin 2830 2097 60 513 40 3.1k
Kazuaki Nishijima 2152 1571 106 648 50 2.6k
Mami Iwamoto 2285 1509 130 1174 15 3.4k
Pedro F. Lopez 2055 1366 73 868 52 2.6k
H. Michael Lambert 1535 1047 52 649 35 1.9k
Catherine Meyerle 2799 1808 96 515 49 3.0k
Anne E. Fung 3043 2328 32 331 36 3.2k
Michael J. Cooney 3251 2192 32 433 40 3.8k
Hadassah Gnessin 1187 849 79 907 10 1.9k

All Works

Loading papers...

Rankless by CCL
2026